Nilay Sethi, Associate Professor at Harvard Medical School, shared Journal of Clinical Investigation’s post on LinkedIn, adding:
“Please share thoughts and feedback on our commentary in The Journal of Clinical Investigation.
Cancer survivorship genomics is an emerging field with plenty of potential to shape clinical care.
How should we interpret mutational signatures in cancer survivors?”
Journal of Clinical Investigation shared on X:
“In this Viewpoint, Xiaolu Wang and Nilay S. Sethi, Dana-Farber consider the biological consequences of treatment for long-term cancer survivors.
Read more: The genomic afterlife of cancer therapy.”
Other articles about genomics on OncoDaily.